Abstract: The invention relates to hair sprays comprising a pressurized container and an aerosol composition, located therein, which includes, based on its weight, 20 to 80% by weight of at least one propellant, 0.1 to 20% by weight of at least one fixing polymer, and 0.01 to 5% by weight of esters of the formula (I), in which R1 stands for —H or —CH3, R2 for a straight-chain or branched alkyl group having 7 to 15 carbon atoms, and n for an integer from the group comprising 1, 2, 3, 4, 5, 6, 7, 8; the hair sprays bring about an improved hair feel, improved lightness of the hairstyle, and improved hair texture, also with further improvement of the hold.

Abstract: The present invention relates generally to the cosmetic treatment of aged skin. More specifically, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in treating photo-aged and/or chronologically-aged skin.

Abstract: A method of correcting the visible and microscopic signs of Dermatoheliosis (chronic ultraviolet light-damaged human skin) and its various clinical manifestations (wrinkling, sagging, fragility, melasma, Poikiloderma of Civatte, solar lentigines, and senile purpura) and also Androgenetic Alopecia and Seborrheic Keratoses consists of the administration of fatty acid derivatives capable of inhibiting mast cells and the mediators they release that cause local tissue damage. These fatty acid derivatives include palmitoylethanolamide (PEA) and related cannabinomimetic compounds and adelmidrol and related Autacoid Local Injury Antagonist amides (ALIAmides) which are administered orally or applied topically. Adelmidrol, the best absorbed topically, is applied in a concentration of between 1% and 10% by volume, with a preferred concentration of about 5% by volume.

Abstract: The present invention provides a glow in the dark staining agent for staining dental plaque includes a first plaque-disclosant comprising a fluorophore having an fluorescence emission after being exposed to a light source, wherein the fluorophore adheres to tooth plaque; and a second plaque-disclosant comprising a dye particle that adheres to tooth plaque and is visible.

Abstract: A method for applying a temporary tattoo ink to an applicator is disclosed, in which the applicator includes a multi-layered pad having a first adhesive layer, a second adhesive layer, an ink-containing layer and a cut-away top layer. A tattoo design is cut into each of the first and second adhesive layers and a temporary tattooing ink is absorbed into the ink containing layer. The temporary tattooing ink includes genipin. The method includes embedding the genipin into the non-woven material by either dipping the ink-containing layer into an aqueous solution of genipin prior to assembling the multi-layered pad or pipetting the genipin onto the assembled applicator.

Abstract: The present invention relates to a broad spectrum stable sunscreen molecule having the general structure (Formula) where “X” is an organic sunscreen belonging to the UVA class and “Y” is an organic sunscreen belonging to UVB class or vice-versa. The invention also relates to a stable sunscreen composition comprising the inventive sunscreen molecule, a UV-B organic sunscreen and a cosmetically acceptable base. The invention also relates to a method of providing UV protection to the sun-exposed parts of human or animal body comprising the step of applying the above composition.

Abstract: Cationic and silicon substituents are introduced into polysaccharides thereby producing modified polysaccharides cationically substituted by quaternary ammonium groups and having a charge density of about 0.1 to about 2.5 meq/g, and further substituted by siliconate groups such that the modified polysaccharide has a silicon content of about 300 to about 5000 ppm. The modified polysaccharides have application in industrial, home care and personal care surface modifying formulations.

Abstract: Disclosed are compositions for washing, cleansing, and/or conditioning keratinous substrates, comprising, in a physiologically acceptable medium: a) at least one anionic film-forming polymer chosen from polymers and copolymers of acrylic acid, methacrylic acid, and/or mixtures thereof; b) at least one ampholytic polymer having at least one acrylic acid moiety and a cationic charge density ranging from greater than 1 meq/g up to about 3.5 meq/g; and c) at least one surfactant base; wherein the at least one anionic film-forming polymer and the at least one ampholytic polymer form an association; and wherein the pH of the composition ranges from about 5 to about 7. Also disclosed are processes for washing, cleansing, and/or conditioning keratin substrates using the composition, and processes for imparting volume to the hair.

Abstract: The invention relates to a composition, especially a cosmetic composition, comprising at least one acrylic thickener and at least one oil, as well as to methods of using such compositions.

Abstract: The present invention relates to an agent for oxidatively coloring or blonding hair that is gentle on the hair, and to a gentle method for oxidatively coloring or blonding hair, in which keratin fibers are protected from oxidative influences.

Abstract: A gel polish composition forming a nail gel film on a keratinous material of mammals comprises a film-forming polymer selected from the group consisting of polyurethane resin, acrylic resin, and mixtures thereof and a method of forming a nail gel film on a keratinous material of mammals comprises: (i) cleansing the keratinous material; (ii) painting a gel polish composition on the keratinous material to form a first layer, wherein the gel polish composition comprises an film-forming polymer, a hydrophilic solvent, a thickening agent, water, and an optional care ingredient; (iii) drying the gel polish composition in air for about 1 minute; (iv) applying a second layer of the gel polish composition; (v) drying the gel polish composition in air for about 1 minute; (vi) optionally applying a third layer; and (vii) peeling off the nail gel film formed on the keratinous material of mammals without using a polish remover.

Abstract: The present invention relates to the use of a peptide and glycoside extract of Schizandra fruit as a cutaneous neurosensory agent, for improving the response of the cutaneous neurosensory system, in particular for: —improving cutaneous innervation in the basal state, —combatting age-related loss of cutaneous innervation in the basal state, advantageously for preventing loss of the cutaneous sensitivity and/or combatting thinning of the epidermis, and/or —improving cutaneous perception of the environment, more particularly for combatting burns, extreme cold and/or pain.

Abstract: The present application relates to probiotic confection-based compositions comprising lactic acid-producing bacteria and oil-based compositions comprising the same.

Abstract: A dispersion including a plurality of bodies dispersed in a continuous phase. Each dispersed body including an internal drop formed with an internal phase miscible with the continuous phase, the internal drop (16) receiving an active product. Each dispersed body including, around the internal drop, a membrane formed with an intermediate phase immiscible with the continuous phase and totally surrounding the internal drop. The ratio R1 of the average thickness (e) of the membrane over the average transverse dimension (Dc) of the active volume delimited by the internal drop and the membrane is greater than 0.05, and is advantageously less than 0.5. The ratio R2 of the partition coefficient of the active product between the intermediate phase forming the membrane and the internal phase forming the internal drop over the viscosity of the membrane is less than 1 s?1·Pa?1.

Abstract: The present application relates to a micelle comprising a drug encapsulated by an amphiphilic polymer and a composition comprising the same. The micelle of the present application has an excellent dispersion property on an aqueous solution and a superior percutaneous absorption characteristic on preparing a formulation.

Abstract: Provided herein are methods for preparing liposomes and uses thereof. In certain embodiments, liposomes are prepared without using heat, organic solvents, proteins, and/or inorganic salts in the process. In certain embodiments, the liposomal preparation contains one or more active agents. In certain embodiments, the liposomal preparations are used in the treatment of diseases or disorders.

Abstract: A multi-component nanochain for use in diagnostic and therapeutic applications includes at least three nanoparticles linked together to form the nanochain. At least one nanoparticle of the nanochain has an asymmetric surface chemistry defined by asymmetrically disposed first linkers and second linkers. The nanoparticles are linked to form the nanochain by linking first linkers and/or second linkers disposed on separate nanoparticles.

Abstract: Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients.

Abstract: Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.

Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.

Abstract: The present invention relates to a composition, in particular a solid pharmaceutical composition comprising a compound having the formula I, as a free base or a salt thereof, and a mixture comprising a vehicle and a non-ionic surfactant in an amount sufficient to achieve solubilization of compound (I); and typically wherein the composition is coated with an enteric coating. Such composition is particularly useful in treatment of cancer.

Abstract: Multistage delivery vehicles are disclosed which include a first stage particle and a second stage particle. The first stage particle is a micro or nanoparticle that contains the second stage particle. The second stage particle includes an active agent, such as a therapeutic agent or an imaging agent. The multistage delivery vehicle allows sequential overcoming or bypassing of biological barriers. The multistage delivery vehicle is administered as a part of a composition that includes a plurality of the vehicles. Methods of making the multistage delivery vehicles are also provided.

Abstract: Disclosed are a controlled release pharmaceutical composition, comprising a melt-extruded pellet including a water-insoluble ammonium methacrylate copolymer, a polyvinyl acetate, and an active ingredient; and a polymer coating layer including a water-insoluble ammonium methacrylate copolymer formed on the surface of the pellet, and an oral formulation including the pharmaceutical composition.

Abstract: A nanocarrier including a silica body having a surface and defining a plurality of pores that are suitable to receive molecules therein is described. The nanocarrier also includes a lipid bilayer coating the surface, and a cargo-trapping agent within the phospholipid bilayer. The phospholipid bilayer stably seals the plurality of pores. The cargo-trapping reagent can be selected to interact with a desired cargo, such as a drug.

Abstract: A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, malic acid, an oxidant, and water, is provided along with temperature conditions to directly form within the reaction mixture, a stable dispersion of nanoceria particles. Biocompatible nanoparticles comprised of ceria and malic acid are described. A reduction in cell death in a murine model of ischemic stroke utilizing intact brain slices is demonstrated by a prophylactic treatment of ceria nanoparticles prepared with malic acid.

Abstract: Disclosed is a fentanyl-containing adhesive preparation for external use, wherein an adhesive layer is laminated on a supporting body. The adhesive layer contains SIS, a tackifier resin that is composed of a rosin resin and terpene resin, and a softener that is composed of a plybutene and a liquid paraffin. The adhesive layer also contains fentanyl as an active ingredient. The fentanyl-containing adhesive preparation for external use has excellent skin permeation of fentanyl and high preparation stability, without suffering from crystallization of fentanyl during storage.

Abstract: The invention relates to a food additive which includes at least one clay interspersed with volatile antimicrobial agents. Such an additive can be added to the feed of certain animals, in particular poultry and ruminants, in order to act as a growth promoter and to reduce the risks of infection, as well as the risks of intoxication by mycotoxins.

Abstract: The technology relates to a method of increasing ractopamine response in a ruminant by feeding a ruminant an animal feed containing a synergistic combination of ractopamine and caffeine to extend the response to ractopamine in the ruminant.

Abstract: Methods of storing and methods of stabilizing pharmaceutical compositions comprising cysteamine, or a pharmaceutically acceptable salt thereof, are provided. Methods of distributing pharmaceutical compositions comprising cysteamine, or a pharmaceutically acceptable salt thereof, and methods of treating cystinosis also are provided.

Abstract: The present invention provides for a novel method for treating polyglutamine (polyQ) diseases. Also disclosed are related compositions and kits for therapeutic use in the treatment of polyQ diseases.

Abstract: Provided are an agent for imparting ceramide-like function, an agent for reinforcing skin barrier function, a moisturizing agent and a skin drug for external use. The agent for imparting ceramide-like function comprises as an effective ingredient a derivative of succinic acid diamide represented by the following formula (1): [wherein R1 and R2 each independently represents a hydroxyalkyl group of from 1 to 6 carbon atoms, R3 represents a group: —CH2CH2CH2CH2—R4 or a group: —CH2CH?CHCH2—R4 (wherein R4 represents an alkyl group of from 8 to 26 carbon atoms)].

Abstract: The present invention relates to hydroxy-substituted amino and ammonium derivatives, in particular the compounds of formula (1) or (2), and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder, or a proliferative, neoplastic or dysplastic disease or disorder.

Abstract: The invention relates to compositions for preventing or delaying the onset of hepatocellular cancer. The compositions of the invention may comprise short chain fatty acids. The compositions of the invention may also comprise probiotic bacteria. The compositions of the invention include compositions for preventing or delaying the onset of hepatocellular cancer by treating or preventing liver inflammation, liver disease, and precancerous lesions.

Abstract: This disclosure provides generally for antimicrobial compositions and methods of use comprising an anthocyanin, an anthocyanidin or metabolites thereof. Methods for promoting healing of a wound using these compositions are also disclosed. These compositions have broad spectrum antimicrobial activity and are safe for human and animal uses. Further, these compositions are safe for medical uses and industrial uses as antiseptic preparations to reduce or prevent microbial growth, including killing bacterial biofilms.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects.

Abstract: The present invention generally refers to an active fraction of an extract of the latex of plants from the family Euphorbiaceae in a polar solvent, as well as of one or more compounds contained therein, as well as the use of said fraction and/or said compounds, particularly in the treatment of cancer. The invention also refers to compositions comprising said active fraction and/or said compounds, as well as their use for the treatment of diseases concerning cell proliferation/angiogenesis, particularly cancer.

Abstract: Described herein are compositions that include an aqueous phase and 5 to 30%, by weight, of an oil phase, based on the total weight of the composition. The oil phase comprises the omega-3 fatty acid triglyceride eicosapentaenoic acid triglyceride, docosahexaenoic acid triglyceride, or mixtures thereof. The composition further comprises at least one amphoteric surfactant, at least one co-surfactant, and at least one co-solvent. The compositions comprise less than 0.03% by weight of sodium oleate, based on the total weight of the composition. Also described are methods for preparing such compositions as well as such compositions for use as a medicament, in particular for use in treating stroke, sepsis, Alzheimer's disease or cancer. Also featured are methods of treating these conditions by parenterally administering a composition to a patient in need and methods of providing parenteral nutrition to such patients by administering to them a composition as described herein.

Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ?-(methylthio)alkylnitriles such as 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Abstract: The invention relates to use of the trans-(E) isomer or isomeric mixtures containing specified ratios of the trans-(E) and cis-(Z) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders.

Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.

Abstract: Disclosures of the present invention describe a method of treatment of preventing hyperglycemia complications using at least one pharmaceutical made from a red mold product, wherein the red mold product is a red mold rice or a red mold Dioscorea, and the pharmaceutical is an extract obtained from the red mold product. Particularly, the extract can be Monascin, Ankaflavin, or a combination of Monascin and Ankaflavin. Moreover, a variety of experiment data have proved that the extract indeed exhibits a prevention effect in hyperglycemia complications comprising non-alcoholic liver damage and kidney failure.

Abstract: Methods for controlling estrogen metabolite formation in a subject and compositions for use therein are disclosed and described. In one aspect, estrogen metabolite formation may be controlled by coadministering an effective amount of a phytoestrogen and an indole compound.

Abstract: The present invention relates to pharmaceutical dosage forms for oral administration comprising the drug substance 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile or any pharmaceutically acceptable salt thereof and to processes of making said solid pharmaceutical dosage forms.

Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Abstract: A medicine for improving the state of pregnancy, which comprises a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient; and a use of the medicine.

Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.

Abstract: Methods for treating and diagnosing psychiatric affective disorders, e.g., an affective disorder associated with aberrant Sonic Hedgehog (Shh) signaling, by administering to the subject a therapeutically effective amount of an antagonist to Smoothened (Smo), an antagonist to Patched-1 (Ptch-1) and/or an antagonist to Shh.

Abstract: This invention provides compositions, kits containing compositions, and methods for their use in treating subjects with pain. Instant compositions comprise two or more long acting aminoamide local anesthetics, at least one NSAID, at least one corticosteroid, at least one alpha-2 (?2) adrenergic receptor agonist, at least one N-methyl-D aspartate receptor antagonist, and optionally, epinephrine. Instant compositions are useful for infiltration anesthesia, field block anesthesia, regional anesthesia, peripheral nerve block, plexus anesthesia, epidural (or extradural) anesthesia, spinal anesthesia, local anesthesia, and transincision catheter anesthesia. The instant compositions have one or more superior properties of analgesia, duration of analgesia, safety, narcotic sparing, and motor sparing properties.

Abstract: Disclosed herein is a new and improved therapy for the treatment of cancer, which comprises the step of altering cell membrane lipid composition by treating a cancer cell with an enzyme inhibitor which inhibits enzymes regulating the cholesterol biosynthetic pathway. One preferred protein target in the cholesterol biosynthetic pathway to inhibit is oxidosqualene cyclase. In some forms, inhibitors of one or more pathways are combined with an existing chemotherapeutic agent to combat drug resistance and enhance the therapeutic efficacy of conventional therapy.